Novo Nordisk, Inc. is a major pharmaceutical company. Its filings show it lobbies on health and federal insurance programs like Medicare and Medicaid, including drug pricing rules tied to the Inflation Reduction Act, coverage of anti-obesity medicines, pharmacy benefit manager reforms, and issues about compounding or counterfeit drugs. It reported hiring the S-3 Group for lobbying work.
Show the dominant industry call, how mixed the client looks, and the allocation across the top labeled sectors.
Annual totals based on disclosed filing amounts.
Issue rankings are based on disclosed activity mentions, with filing amounts apportioned evenly across issues within the same filing.
The lobbying registrants handling this client, ranked by disclosed filing amounts.
Lobbyists are ranked by appearances and an equal share of each filing's reported amount.
CHRISTOPHER BUKI
The latest disclosures for this client.
S-3 GROUP
Q1S-3 GROUP
RRThe entities named in disclosed activities are the clearest available signal for where the client is aiming attention.
S-3 GROUP
KEVIN CASEY
S-3 GROUP
MALLOY MCDANIEL
S-3 GROUP
MICHAELEEN EARLE CROWELL
S-3 GROUP
mr MARTIN REISER
S-3 GROUP
OLIVIA KURTZ
S-3 GROUP